STEP 3 trial results showed average weight loss of 16.0% with semaglutide and 5.7% with placebo, an inactive injection, over 68 weeks. Both groups received intensive help with eating and activity. The difference between them was 10.3 percentage points; the full 16% wasn't the medication's added effect alone.
What question did STEP 3 ask?
Could semaglutide add to weight loss when people already had substantial support with food, activity and daily habits?
Thomas Wadden and colleagues reported STEP 3 in JAMA in 2021. The trial record, NCT03611582, describes the planned comparison. Researchers assigned people by chance to semaglutide or placebo. Participants and study staff didn't know who received which treatment.
There was no group receiving medication without the behavioral program. That matters when someone describes these results as what the medicine does by itself.
Who took part, and for how long?
The trial enrolled 611 adults at 41 U.S. sites: 407 received semaglutide and 204 received placebo. Their average age was 46; 81% were women.
People could qualify with a BMI, a measure of weight relative to height, of at least 30. A BMI of at least 27 qualified with a weight-related condition, such as high blood pressure.
People with diabetes were excluded. Other exclusions included weight change greater than 5 kg, about 11 pounds, within 90 days, and previous or planned weight-loss surgery or devices.
Treatment lasted 68 weeks, followed by seven weeks of safety follow-up. Of all participants, 567 completed the trial, while 505 were still receiving assigned treatment at its end. Finishing follow-up and staying on medication were different measures.
The STEP 3 low-calorie diet and behavioral program
Both groups began with eight weeks of meal replacements providing 1,000–1,200 calories daily. They then moved to ordinary foods with study targets of 1,200–1,800 calories, based on starting weight.
Activity targets rose from 100 to 200 minutes weekly. The program scheduled 30 individual counseling visits: weekly through week 12, every other week through week 24, then every four weeks. Sessions covered food and activity records, practical barriers and support from others.
Thirty was the scheduled visit count, rather than a reported average attendance. It doesn't mean everyone completed every session.
The intended semaglutide dose was 2.4 mg weekly, reached through gradual increases over 16 weeks. These were supervised study conditions. An individual's prescriber sets the actual dose.
What did the researchers measure?
The co-primary endpoints, the two main measurements chosen beforehand, were percentage weight change and the share losing at least 5% by week 68.
An estimand is the exact question an analysis answers. The main treatment policy analysis counted people in their assigned groups even after medication stopped or other weight-management treatment began. Researchers estimated missing measurements using available trial data.
A separate analysis assumed everyone stayed on assigned treatment without other weight-management treatment. Its larger figures answer a different question.
STEP 3 trial results at 68 weeks
Average weight loss was 16.0% versus 5.7%. The paper's estimated gap was 10.3 percentage points, meaning the difference between those two percentages.
About seven in eight semaglutide participants with measurements lost at least 5%, compared with about half receiving placebo.
| Outcome at week 68 | Semaglutide plus program | Placebo plus program |
|---|---|---|
| Average weight change, main analysis | −16.0% | −5.7% |
| Lost at least 5% | 86.6% | 47.6% |
| Lost at least 15%, an additional measure | 55.8% | 13.2% |
The threshold percentages use available measurements from 373 semaglutide participants and 189 placebo participants. They aren't percentages of everyone originally assigned.
The analysis assuming continued treatment estimated 17.6% versus 5.0% weight loss. Its reported gap was 12.7 percentage points, calculated before rounding the displayed averages.
The placebo result matters: it came with the same substantial support. STEP 3 cannot divide that group's loss into separate effects of meal replacements, counseling and activity.
What side effects appeared in STEP 3?
About four in five semaglutide participants reported stomach or bowel problems. Most were mild to moderate, but some led to treatment stopping.
An adverse event is a health problem recorded during a study; recording it doesn't prove the medicine caused it. These selected rows come from the paper's Table 3. They count people, rather than repeated symptom episodes, using 407 semaglutide and 204 placebo participants.
| Recorded event or treatment stop | Semaglutide | Placebo |
|---|---|---|
| Any stomach or bowel disorder | 82.8% | 63.2% |
| Nausea | 58.2% | 22.1% |
| Constipation | 36.9% | 24.5% |
| Diarrhea | 36.1% | 22.1% |
| Vomiting | 27.3% | 10.8% |
| Serious event, such as one requiring hospitalization | 9.1% | 2.9% |
| Gallbladder-related disorder | 4.9% | 1.5% |
| Stopped because of any adverse event | 5.9% | 2.9% |
| Stopped because of stomach or bowel events | 3.4% | 0% |
These figures use the table's on-treatment window, the period it counted as exposure to study medication. Fourteen semaglutide participants stopped because of digestive events; none receiving placebo did.
As of November 12, 2026, the day this article was written, FDA's November 9 safety communication requires warnings about a potential increased risk of NAION across this medicine family. NAION is an eye condition involving reduced blood flow to the nerve carrying sight; it can cause permanent vision loss. FDA says patients with sudden vision loss, blurred or missing vision, or distorted colors should contact their health care professional right away.
What critics and later trials added
In a 2021 JAMA letter, Christopher Rayner and colleagues questioned how digestive symptoms were recorded. Participants reported symptoms without a validated measure, a tool tested for how well it captures those symptoms.
The STEP 3 authors also acknowledged that their design couldn't establish how much extra benefit came from intensive counseling or meal replacements. Comparing its headline with STEP 1's results doesn't settle that question: people weren't assigned by chance between the two programs.
Longer treatment needed separate evidence. STEP 5, reported by Garvey and colleagues in Nature Medicine in 2022, followed 304 adults for 104 weeks. Average weight change was −15.2% with semaglutide versus −2.6% with placebo, alongside behavioral support. That adds longer observation, without isolating the value of STEP 3's intensive program.
The Wegovy STEP 4 trial asked another question: continuation versus withdrawal after everyone first received semaglutide. It isn't an extension of STEP 3.
What this means for a compounded prescription
STEP 3 studied a defined trial product and program. It didn't test Promise's preparation or establish that a compounded prescription would produce the same results.
Semaglutide prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.
As of November 12, 2026, the day this article was written, FDA's compounding explanation states that it doesn't verify compounded drugs' safety, effectiveness or quality before marketing.
A licensed provider may still prescribe — that decision is between you and your doctor.
At Promise, a licensed provider reviews every request, and not everyone qualifies. Trial averages inform that conversation alongside medical history, other medicines, tolerable side effects and the support someone can realistically maintain.





